Literature DB >> 21483260

Herpes simplex virus encephalitis: new infection or reactivation?

Israel Steiner1.   

Abstract

PURPOSE OF REVIEW: This review describes the pathogenesis, clinical presentation, course, and therapy of herpes simplex encephalitis (HSE), the most fatal viral encephalitis, in which prognosis is dependent on early diagnosis and effective therapy. RECENT
FINDINGS: Herpes simplex viruses types 1 and 2 (HSV-1 and HSV-2) are human neurotropic viruses that establish latent infection in dorsal-root ganglia for the entire life of the host. From this reservoir, they can reactivate to cause human morbidity and mortality. HSE is one of the most devastating disorders caused by these viruses. The biology of their ability to establish latency, maintain it for the entire life of the host, reactivate, and cause primary and recurrent disease is being studied in animal models and in humans. Of special interest is the question whether HSE is the result of primary infection or is it the outcome of reactivation. The present review covers the biological, medical, and neurological aspects of HSE, focusing among others on recent molecular findings of gene expression during latent infection of HSV-1.
SUMMARY: Despite accumulating knowledge, there are still several issues regarding both pathogenesis and therapy of HSV-1 that currently defy understanding.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21483260     DOI: 10.1097/WCO.0b013e328346be6f

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  38 in total

1.  Modulation of reactivation of latent herpes simplex virus 1 in ganglionic organ cultures by p300/CBP and STAT3.

Authors:  Te Du; Guoying Zhou; Bernard Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-20       Impact factor: 11.205

2.  Resident T Cells Are Unable To Control Herpes Simplex Virus-1 Activity in the Brain Ependymal Region during Latency.

Authors:  Chandra M Menendez; Jeremy K Jinkins; Daniel J J Carr
Journal:  J Immunol       Date:  2016-06-29       Impact factor: 5.422

Review 3.  Antimicrobial actions of dual oxidases and lactoperoxidase.

Authors:  Demba Sarr; Eszter Tóth; Aaron Gingerich; Balázs Rada
Journal:  J Microbiol       Date:  2018-06-01       Impact factor: 3.422

Review 4.  Herpes Simplex Virus-1 Encephalitis in Adults: Pathophysiology, Diagnosis, and Management.

Authors:  Michael J Bradshaw; Arun Venkatesan
Journal:  Neurotherapeutics       Date:  2016-07       Impact factor: 7.620

5.  A NK complex-linked locus restricts the spread of herpes simplex virus type 1 in the brains of C57BL/6 mice.

Authors:  Lorne F Kastrukoff; Allen S Lau; Fumio Takei; Francis R Carbone; Anthony A Scalzo
Journal:  Immunol Cell Biol       Date:  2015-05-14       Impact factor: 5.126

Review 6.  Update on progressive multifocal leukoencephalopathy.

Authors:  Israel Steiner; Joseph R Berger
Journal:  Curr Neurol Neurosci Rep       Date:  2012-12       Impact factor: 5.081

Review 7.  Mechanisms of Blood-Brain Barrier Disruption in Herpes Simplex Encephalitis.

Authors:  Hui Liu; Ke Qiu; Qiang He; Qiang Lei; Wei Lu
Journal:  J Neuroimmune Pharmacol       Date:  2018-11-19       Impact factor: 4.147

8.  Microglia-induced IL-6 protects against neuronal loss following HSV-1 infection of neural progenitor cells.

Authors:  Ana J Chucair-Elliott; Christopher Conrady; Min Zheng; Chandra M Kroll; Thomas E Lane; Daniel J J Carr
Journal:  Glia       Date:  2014-05-07       Impact factor: 7.452

9.  Virological diagnosis of central nervous system infections by use of PCR coupled with mass spectrometry analysis of cerebrospinal fluid samples.

Authors:  Nicolas Lévêque; Jérôme Legoff; Catherine Mengelle; Séverine Mercier-Delarue; Yohan N'guyen; Fanny Renois; Fabien Tissier; François Simon; Jacques Izopet; Laurent Andréoletti
Journal:  J Clin Microbiol       Date:  2013-11-06       Impact factor: 5.948

Review 10.  Recent issues in herpes simplex encephalitis.

Authors:  Peter G E Kennedy; Israel Steiner
Journal:  J Neurovirol       Date:  2013-06-18       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.